Other languages Mesoblast Limited Nasdaq

Equities

MESO

US5907174016

Real-time Estimate Cboe BZX Other stock markets 09:39:13 2024-04-25 am EDT			5-day change	1st Jan Change
6.02 ^USD	-3.22%		+24.15%	+182.73%

Apr. 01	ADRs End Higher; Connect Biopharma Climbs 26%	DJ
Mar. 28	ADRs End Lower; NuCana Slides 15%	DJ

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

FDA Says Mesoblast Trial Data Sufficient to Support BLA Submission	Mar. 26
Sector Update: Health Care Stocks Advance Late Afternoon	Mar. 26
Top Midday Gainers	Mar. 26
Sector Update: Health Care Stocks Steady Premarket Tuesday	Mar. 26
Wall Street Set to Open Modestly Higher Tuesday Ahead Consumer Confidence Reading	Mar. 26
Top Premarket Gainers	Mar. 26
Mesoblast to Resubmit Application for Potential Pediatric Treatment of Graft Versus Host Disease; Shares Gain Pre-Bell	Mar. 26
United States Food & Drug Administration Notifies Mesoblast Limited of Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease	Mar. 25
Mesoblast Raises AU$97 Million From Entitlement Offer, Institutional Placement	Mar. 14
Mesoblast Raises AU$97 Million for Phase Three Registration Trials	Mar. 14
Sector Update: Health Care Stocks Softer Late Afternoon	Mar. 11
Sector Update: Health Care Stocks Decline in Afternoon Trading	Mar. 11
Sector Update: Health Care	Mar. 11
Top Stories at Midday: Bally's Gets Takeover Proposal; Eli Lilly's Eczema Study Results; Reddit's Expected IPO Price Range; FDA Backs Mesoblast Heart Therapy's Approval Pathway	Mar. 11
Sector Update: Health Care Stocks Lean Lower Premarket Monday	Mar. 11
Mesoblast Secures Backing from US FDA for Potential Fast-Track Approval of Heart Failure Treatment	Mar. 11
Mesoblast Limited Announces United States Food & Drug Administration Supports Accelerated Approval Pathway for Rexlemestrocel-L in End-Stage Heart Failure Patients with A Left Ventricular Assist Device	Mar. 10
Mesoblast Narrows H1 FY24 Loss; Shares Down 3%	Feb. 28
Mesoblast Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 28
Mesoblast Says FDA Grants Orphan Drug Designation for Revascor in Children With Congenital Heart Disease	Feb. 15

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Mesoblast Limited Nasdaq

Equities

MESO

US5907174016

Other languages

Filters